Pet Cancer Therapeutics Market: Size, Share, Trends, Global Opportunity Analysis and Forecast, 2025 | Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.
 |
| Pet Cancer Therapeutics |
The diagnostic and therapy options for malignant and tumour growth in domesticated animals are referred to as pet cancer therapies. It treats lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer in dogs, cats, and other pets. Chemotherapy, immunotherapy, radiation treatment, and biopsy are some of the most often utilised therapies.
These treatments use plant- and bacteria-based medications to gradually destroy or shrink cancer cells, preventing the tumour from spreading to other regions of the body. Orally or intravenously, the medications are injected under the skin, into a muscle, or into the tumour. They're added to food or treats to conceal the taste and make it more enticing to dogs.
Due to increased consumer expenditure on pet healthcare, the pet cancer therapeutics market is expected to rise significantly. People are getting more concerned about their pets' health and spending more money on the greatest animal therapies accessible.
A rise in the number of pet owners and a rise in the number of pets diagnosed with cancer might extend the pet cancer therapeutics market. Pet adoption may increase at a gradual rate over time as more individuals seek companionship in affluent countries. Every year, there appears to be a 2% increase in pet ownership.
One of the primary reasons driving the pet cancer therapeutics market growth is the rising occurrence of cancer in animals throughout the world. Furthermore, the growing domestication of animals and public awareness about pet health are propelling the industry forward. Long-term exposure to ultraviolet (UV) rays, second-hand cigarette smoke, herbicides, pesticides, insecticides, and air pollution can induce leukaemia and lymphoma in cats and some breeds of older dogs.
As a result, the market is growing as people become more aware of the benefits of early diagnosis and the treatment options that are available. Various technical breakthroughs, such as the development of highly focused and precise treatments for pet cancer therapeutics with low side effects, are also boosting the industry. Other factors such as increasing consumer spending capacity on pet healthcare and substantial research and development (R&D) efforts in the field of veterinary oncology are expected to propel the market forward.
The major key players operating the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.
A rise in the number of pet owners and a rise in the number of pets diagnosed with cancer might extend the pet cancer therapeutics market. Pet adoption may increase at a gradual rate over time as more individuals seek companionship in affluent countries. Every year, there appears to be a 2% increase in pet ownership.
One of the primary reasons driving the pet cancer therapeutics market growth is the rising occurrence of cancer in animals throughout the world. Furthermore, the growing domestication of animals and public awareness about pet health are propelling the industry forward. Long-term exposure to ultraviolet (UV) rays, second-hand cigarette smoke, herbicides, pesticides, insecticides, and air pollution can induce leukaemia and lymphoma in cats and some breeds of older dogs.
As a result, the market is growing as people become more aware of the benefits of early diagnosis and the treatment options that are available. Various technical breakthroughs, such as the development of highly focused and precise treatments for pet cancer therapeutics with low side effects, are also boosting the industry. Other factors such as increasing consumer spending capacity on pet healthcare and substantial research and development (R&D) efforts in the field of veterinary oncology are expected to propel the market forward.
The major key players operating the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.
Comments
Post a Comment